Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Cetuximab vs Usual Care in Stage II/III BRAF V600E Colon Cancer
NCT05710406Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2023
- Primary completion
- Jun 2034
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of encorafenib, KL-140 in colon adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Aug 2023; status: active, not recruiting.
02
Drugs
encorafenibKL-140
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on NCT05710406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710406.